Pfizer, a major American pharmaceutical company, and Biontech, a German company, have released a new analysis of clinical trials that the vaccine for the new coronavirus developed is 91.3% effective six months after the second vaccination. ..
Pfizer and Biontech are still conducting clinical trials of the new coronavirus vaccine they have developed, even after the US FDA (Food and Drug Administration) issued an emergency use authorization last December.
According to a new analysis released on the 1st, of the 46,000 participants, 927 had confirmed symptoms of coronavirus infection by the 13th of last month.
Of these,
▼ 850 were in the group receiving a placebo called "placebo" and
▼ 77 were in the group vaccinated, with an
efficacy of 91.3% from 7 days to 6 months after the second vaccination. I will.
More than 12,000 of the participants have been inoculated for half a year since the second inoculation, and Pfizer and others have stated that "this result shows that the effect will continue until half a year later."
In addition, in a clinical trial conducted in South Africa with 800 people enrolled, all 9 patients with confirmed symptoms of coronavirus infection were in the group receiving "placebo", and 6 of them were confirmed in South Africa. The vaccine was shown to be highly effective against South African mutant viruses because it was a mutant virus.
Pfizer and Biontech say they will promptly share the results of this analysis with regulators in each country.